Perspective is advancing multiple clinical programs across a range of tumors, and is using its proprietary platform to generate a robust pipeline novel pre-IND assets.
| PROGRAM (TARGET) |
TARGET DISEASE | CANDIDATE EVALUATION | HUMAN CLINICAL IMAGING | PHASE 1/2 | REGISTRATION ENABLING STUDY | STATUS |
|---|---|---|---|---|---|---|
| VMT01/02 (MC1R) |
Melanoma (MC1R Imaging & Therapy) |
|
Enrolling
Enrolling |
|||
| VMT-α-NET (SSTR2) |
Neuroendocrine Tumors Other SSTR2 Expressing Tumors |
|
Cohort 2: Enrolling Cohort 3: Open for enrollment Under evaluation |
|||
| PSV359 (FAP-α) |
Multiple Solid Tumors | Enrolling | ||||
| PSV4XX (PSMA) | Prostate (PSMA Imaging & Therapy) |
Under evaluation | ||||
| Undisclosed Program 5 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 6 | Multiple Solid Tumors | Under evaluation | ||||
| Undisclosed Program 7 | Multiple Solid Tumors | Under evaluation | ||||
| Pre-Targeting Platform | Multiple Solid Tumors | Under evaluation | ||||